MANNKIND CORP (MNKD) 4.57 -0.04 (-0.87%)
4.57 -0.04 (-0.87%)
US56400P7069 - Common Stock - After market: 4.57 0 (0%)
Fundamental Rating
Overall MNKD gets a fundamental rating of 3 out of 10. We evaluated MNKD against 635 industry peers in the Biotechnology industry. MNKD has a medium profitability rating, but doesn't score so well on its financial health evaluation. MNKD is quite expensive at the moment. It does show a decent growth rate.
Profitability
Profitability Rating
MNKD's Return On Assets of -33.19% is amongst the best of the industry. MNKD does better than the industry average Return On Assets of -44.83%.
MNKD has a Profit Margin of -127.93%. This is better than the industry average of -464.10%.
MNKD has negative profitability rations, so we won't be analyzing them here.
The Piotroski-F score of MNKD is 3.00. This is a low score and indicates issues in the health and profitability of MNKD.
VS Industry
ROA (-33.19%) VS Industry: 67% outperformed.
-3,944.82
115.38
Profit Margin (-127.93%) VS Industry: 69% outperformed.
-1,173,705.71
34,743.00
Valuation
Valuation Rating
The Price/Earnings Ratio is negative for MNKD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MNKD. No positive earnings are expected for the next year.
VS Industry
Growth
Growth Rating
The Earnings Per Share is expected to grow by 22.16% on average over the next 5 years. This is a very strong growth
Based on estimates for the next 5 years, MNKD will show a very strong growth in Revenue. The Revenue will grow by 47.59% on average per year.
The Revenue growth is accelerating: in the next 5 years the growth will be better than in the last years.
Looking at the last year, MNKD shows a decrease in Revenue. The Revenue has decreased by -6.23% in the last year.
The earnings per share for MNKD have decreased strongly by -111.11% in the last year.
The Revenue for MNKD have been decreasing by -15.47% on average. This is quite bad
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | N/A | N/A | -111.11% | -60.01% | 18.49% | 42.15% | 22.16% |
| Revenue | -15.47% | 39.32% | -6.23% | 12.9% | 45.59% | 52.09% | 47.59% |
Health
Health Rating
A Current Ratio of 3.66 indicates that MNKD has no problem at all paying its short term obligations.
A Quick Ratio of 3.36 indicates that MNKD has no problem at all paying its short term obligations.
When comparing the Current Ratio of MNKD to the average industry Current Ratio of 6.11, MNKD is less able to pay its short term obligations than its industry peers.
Compared to an average industry Quick Ratio of 6.02, MNKD is worse placed to pay its short term obligations than its industry peers.
The Debt to Equity ratio of MNKD is negative (-1.55). This means it has negative shareholder equity as the company's liabilities exceed its assets. This could be considered a sign of high risk.
MNKD has an Altman-Z score of -13.86. This is a bad value and indicates that MNKD is not financially healthy and even has some risk of bankruptcy.
When comparing the Altman-Z score of MNKD to the average industry Altman-Z score of -0.65, MNKD is less financially healthy than its industry peers. 89% of its industry peers have a better Altman-Z score.
MNKD has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of MNKD.
VS Industry
Quick Ratio (3.36) VS Industry: 29% outperformed.
0.02
84.53
Current Ratio (3.66) VS Industry: 31% outperformed.
0.02
85.09
Altman-Z (-13.86) VS Industry: 11% outperformed.
-1,822.12
441.73
Dividend
Dividend Rating
MNKD does not give a dividend.
MANNKIND CORP4.57
NASDAQ:MNKD (12/6/2022, 7:00:01 PM)-0.04 (-0.87%)
| GICS Sector | Health Care | ||
| GICS IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences | ||
| GICS Industry | Biotechnology | ||
| Earnings (Last) | 11-08 2022-11-08/bmo | Earnings (Next) | 02-22 2023-02-22 |
| Ins Owners | 2.62% | Inst Owners | 49.36% |
| Market Cap | 1.20B | Analysts | 85 |
| PE | N/A | Fwd PE | N/A |
| PEG (NY) | N/A | PEG (5Y) | N/A |
| P/S | 15.78 | P/B | N/A |
| EV/EBITDA | -17.25 | ||
| Dividend Yield | N/A | Dividend Growth | N/A |
| DP | N/A | Ex-Date | N/A |
| EPS 1Y | -111.11% | EPS 3Y | N/A |
| EPS 5Y | N/A | EPS growth Q2Q | -200% |
| EPS Next Y | -60.01% | EPS Next 2Y | 18.49% |
| EPS Next 3Y | 42.15% | EPS Next 5Y | 22.16% |
| Revenue growth 1Y | -6.23% | Revenue growth 3Y | 39.32% |
| Revenue growth 5Y | -15.47% | Revenue growth Q2Q | 47.79% |
| Revenue Next Year | 12.9% | Revenue Next 2Y | 45.59% |
| Revenue Next 3Y | 52.09% | Revenue Next 5Y | 47.59% |
| Current Ratio | 3.66 | Quick Ratio | 3.36 |
| Altman-Z | -13.86 | F-Score | 3 |
| Debt/Equity | -1.55 | WACC | 9.09% |
| ROIC/WACC | N/A | ||
| ROA | -33.19% | ROE | N/A |
| ROICexgc | N/A | ROIC | N/A |
| PM | -127.93% | OM | -111.69% |
| Asset Turnover | 0.26 | ||
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA